595 related articles for article (PubMed ID: 18559703)
1. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia.
Powell RJ; Simons M; Mendelsohn FO; Daniel G; Henry TD; Koga M; Morishita R; Annex BH
Circulation; 2008 Jul; 118(1):58-65. PubMed ID: 18559703
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic angiogenesis for critical limb ischemia: microvascular therapies coming of age.
Tongers J; Roncalli JG; Losordo DW
Circulation; 2008 Jul; 118(1):9-16. PubMed ID: 18591450
[No Abstract] [Full Text] [Related]
3. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia.
Shigematsu H; Yasuda K; Iwai T; Sasajima T; Ishimaru S; Ohashi Y; Yamaguchi T; Ogihara T; Morishita R
Gene Ther; 2010 Sep; 17(9):1152-61. PubMed ID: 20393508
[TBL] [Abstract][Full Text] [Related]
4. A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia.
Gu Y; Zhang J; Guo L; Cui S; Li X; Ding D; Kim JM; Ho SH; Hahn W; Kim S
J Gene Med; 2011 Nov; 13(11):602-10. PubMed ID: 22015632
[TBL] [Abstract][Full Text] [Related]
5. Clinical Safety and Preliminary Efficacy of Plasmid pUDK-HGF Expressing Human Hepatocyte Growth Factor (HGF) in Patients with Critical Limb Ischemia.
Cui S; Guo L; Li X; Gu Y; Fu J; Dong L; Song H; Chen X; Lu Y; Hu C; Xiao F; Zhu D; Wu Z; Zhang Q
Eur J Vasc Endovasc Surg; 2015 Oct; 50(4):494-501. PubMed ID: 26122834
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial.
Powell RJ; Goodney P; Mendelsohn FO; Moen EK; Annex BH;
J Vasc Surg; 2010 Dec; 52(6):1525-30. PubMed ID: 21146749
[TBL] [Abstract][Full Text] [Related]
7. Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase I study.
Henry TD; Hirsch AT; Goldman J; Wang YL; Lips DL; McMillan WD; Duval S; Biggs TA; Keo HH
Gene Ther; 2011 Aug; 18(8):788-94. PubMed ID: 21430785
[TBL] [Abstract][Full Text] [Related]
8. Transcutaneous oxygen tension (TcPO2) in the testing period of spinal cord stimulation (SCS) in critical limb ischemia of the lower extremities.
Petrakis IE; Sciacca V
Int Surg; 1999; 84(2):122-8. PubMed ID: 10408282
[TBL] [Abstract][Full Text] [Related]
9. A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia.
Gu Y; Cui S; Wang Q; Liu C; Jin B; Guo W; Liu C; Chu T; Shu C; Zhang F; Han C; Liu Y
Mol Ther; 2019 Dec; 27(12):2158-2165. PubMed ID: 31805256
[TBL] [Abstract][Full Text] [Related]
10. Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. The Oral Iloprost in severe Leg Ischaemia Study Group.
Eur J Vasc Endovasc Surg; 2000 Oct; 20(4):358-62. PubMed ID: 11038148
[TBL] [Abstract][Full Text] [Related]
11. [Autologous bone-marrow stem-cell transplantation for induction of arteriogenesis for limb salvage in critical limb ischaemia].
Amann B; Lüdemann C; Ratei R; Schmidt-Lucke JA
Zentralbl Chir; 2009 Aug; 134(4):298-304. PubMed ID: 19688676
[TBL] [Abstract][Full Text] [Related]
12. The best TcpO(2) parameters to predict the efficacy of spinal cord stimulation to improve limb salvage in patients with inoperable critical leg ischemia.
Ubbink DT; Gersbach PA; Berg P; Amann W; Gamain J
Int Angiol; 2003 Dec; 22(4):356-63. PubMed ID: 15153819
[TBL] [Abstract][Full Text] [Related]
13. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia.
Gu YQ; Zhang J; Guo LR; Qi LX; Zhang SW; Xu J; Li JX; Luo T; Ji BX; Li XF; Yu HX; Cui SJ; Wang ZG
Chin Med J (Engl); 2008 Jun; 121(11):963-7. PubMed ID: 18706241
[TBL] [Abstract][Full Text] [Related]
14. Transcutaneous oxygen pressure as predictive parameter for ulcer healing in endstage vascular patients treated with spinal cord stimulation.
Claeys LG; Horsch S
Int Angiol; 1996 Dec; 15(4):344-9. PubMed ID: 9127776
[TBL] [Abstract][Full Text] [Related]
15. Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia.
Morishita R; Makino H; Aoki M; Hashiya N; Yamasaki K; Azuma J; Taniyama Y; Sawa Y; Kaneda Y; Ogihara T
Arterioscler Thromb Vasc Biol; 2011 Mar; 31(3):713-20. PubMed ID: 21183732
[TBL] [Abstract][Full Text] [Related]
16. Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularization.
Marston WA; Davies SW; Armstrong B; Farber MA; Mendes RC; Fulton JJ; Keagy BA
J Vasc Surg; 2006 Jul; 44(1):108-114. PubMed ID: 16828434
[TBL] [Abstract][Full Text] [Related]
17. Transfection of human HGF plasmid DNA improves limb salvage in Buerger's disease patients with critical limb ischemia.
Shigematsu H; Yasuda K; Sasajima T; Takano T; Miyata T; Ohta T; Tanemoto K; Obitsu Y; Iwai T; Ozaki S; Ogihara T; Morishita R;
Int Angiol; 2011 Apr; 30(2):140-9. PubMed ID: 21427651
[TBL] [Abstract][Full Text] [Related]
18. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia.
Matoba S; Tatsumi T; Murohara T; Imaizumi T; Katsuda Y; Ito M; Saito Y; Uemura S; Suzuki H; Fukumoto S; Yamamoto Y; Onodera R; Teramukai S; Fukushima M; Matsubara H;
Am Heart J; 2008 Nov; 156(5):1010-8. PubMed ID: 19061721
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte growth factor as potential cardiovascular therapy.
Nakagami H; Kaneda Y; Ogihara T; Morishita R
Expert Rev Cardiovasc Ther; 2005 May; 3(3):513-9. PubMed ID: 15889978
[TBL] [Abstract][Full Text] [Related]
20. Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial.
Kawamoto A; Katayama M; Handa N; Kinoshita M; Takano H; Horii M; Sadamoto K; Yokoyama A; Yamanaka T; Onodera R; Kuroda A; Baba R; Kaneko Y; Tsukie T; Kurimoto Y; Okada Y; Kihara Y; Morioka S; Fukushima M; Asahara T
Stem Cells; 2009 Nov; 27(11):2857-64. PubMed ID: 19711453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
